# Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

> **NCT04485039** · PHASE4 · COMPLETED · sponsor: **SIGA Technologies** · enrollment: 44 (actual)

## Conditions studied

- Smallpox

## Interventions

- **DRUG:** Tecovirimat
- **DRUG:** sevelamer carbonate oral tablet
- **DRUG:** sucroferric oxyhydroxide chewable tablet
- **DRUG:** calcium acetate oral tablet
- **DRUG:** Lanthanum Carbonate Chewable Tablet

## Key facts

- **NCT ID:** NCT04485039
- **Lead sponsor:** SIGA Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-08
- **Primary completion:** 2022-12-15
- **Final completion:** 2023-04-23
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-12-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04485039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04485039, "Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT04485039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*